|MadSci Network: Immunology|
Recently, the role of dendritic cells has been a focus of studies relating to transplant rejection and autoimmune diseases. Maximizing the tolerogenic properties of these antigen presenting cells is desirable and may help achieve the goal of long-term allograft survival. Many agents have been shown to inhibit dendritic cell maturation in vitro, resulting in increased tolerogenicity. Though I have done much research (including on web resources such as Medline and PubMed I lack an understanding of the potential method of use of these agents (eg. IL-10 and TFG beta). Would they be used as systemic antirejection therapy, and if so, would the body's ability to fight invading pathogens be limited? (I am currently in the research stages of a science project and considering comparing the ability of these different agents to inhibit dendritic cell maturation. I would very much appreciate some help with this question.) Thank you.
Re: How can the inhibition of dendritic cell maturation in vitro be applied?
Try the links in the MadSci Library for more information on Immunology.